Castle Biosciences Champions Skin Cancer Awareness Initiatives
The Company continues its collaborations with leading melanoma organizations to promote education and awareness throughout the month dedicated to skin cancer.
Castle Biosciences, Inc. (Nasdaq: CSTL), a trailblazer in innovative health solutions, is taking significant strides this May to recognize Skin Cancer Awareness Month. The Company's initiatives aim to elevate awareness, educate patients and their loved ones, and empower those affected by skin cancer.
"At Castle, our commitment lies in delivering actionable information that patients and their clinical teams can rely on," stated Derek Maetzold, president and chief executive officer. "Awareness and education are the cornerstones of improved outcomes, and through our support of organizations like IMPACT Melanoma and sharing authentic patient stories, we strive to foster essential conversations on early detection and personalized risk assessment."
Empowering Patients Through Educational Events
Castle proudly continues its partnership with IMPACT Melanoma by sponsoring an upcoming virtual patient symposium, titled "Melanoma Diagnosis: A Toolkit to Support the Journey." Scheduled for the evening of May 21, this symposium is designed for individuals newly diagnosed with melanoma and their support systems, offering valuable tools and compassionate guidance throughout their journey.
Leading this compelling discussion will be Dr. Aaron Farberg, a double board-certified dermatologist and chief medical officer of Bare Dermatology. He will be joined by dedicated dermatology students who will help guide the discussion on crucial topics including navigating a diagnosis, emotional support resources, and survivorship planning. Participants can gain insights into advocating more effectively for their melanoma care.
Inspiring Stories of Survival
A highlight of Castle’s initiatives is the poignant story of Leah Adams, a melanoma survivor who benefitted from Castle’s DecisionDx-Melanoma test. This test helped her grasp her risk of recurrence. Leah emphasizes, "Many people don’t realize how serious melanoma is. The DecisionDx-Melanoma test provides clarity on your risk, which is vital for protecting your skin health. Knowing my low-risk status enables me to focus on my family and personal well-being." Leah's story serves as a beacon of hope for many.
Walking Towards a Cure: Advocacy Efforts
In its commitment to advancing skin cancer awareness, Castle continues its support of AIM at Melanoma and the Melanoma Research Foundation by participating in various advocacy walks throughout May. These gatherings unite survivors, caregivers, healthcare providers, and advocates, fostering a community dedicated to raising funds for research, education, and outreach, all in pursuit of finding a cure.
National Awareness Campaigns
This month, Castle is also involved in the 2025 Skin Health Campaign orchestrated by USA TODAY. The Company is collaborating on a feature article titled "Transforming Skin Cancer and Melanoma Outcomes," scheduled for the May print edition and digital platforms.
Leading voices in the article include Dr. Shannon Trotter, a renowned dermatologist and melanoma advocate Leah Adams. This feature emphasizes the critical role diagnostic testing plays in personalized care for melanoma patients, showcasing how it can enhance treatment decisions.
Comprehensive Solutions for Patient Care
Castle Biosciences offers a portfolio of innovative tests designed for various skin cancers, including its acclaimed DecisionDx-Melanoma. The Company’s tests empower healthcare providers with data to guide individual patient care effectively. By integrating tumor biology and clinical factors, these tests provide essential insights into risk stratification, helping providers choose the most appropriate management strategies.
As the landscape of skin cancer treatment evolves, Castle is also exploring advancements in therapies for conditions such as atopic dermatitis. The Company remains committed to research and development, aiming to address high clinical needs in patient care.
Supporting Advocacy and Research Organizations
Castle’s collaboration with organizations like IMPACT Melanoma, AIM at Melanoma, and the Melanoma Research Foundation highlights their dedication to education and advocacy. Each organization plays a pivotal role in creating awareness programs, providing resources for patients, and influencing health policies that address shade equity and prevention education.
Frequently Asked Questions
What is Castle Biosciences' mission?
Castle Biosciences aims to improve health outcomes by delivering innovative diagnostic tests that guide patient care decisions.
How does the DecisionDx-Melanoma test help patients?
This test provides patients with a personalized assessment of their likelihood of melanoma recurrence, allowing for informed decisions in their care path.
What events is Castle participating in for Skin Cancer Awareness Month?
Castle is sponsoring the IMPACT Melanoma virtual patient symposium and hosting advocacy walks with AIM at Melanoma and the Melanoma Research Foundation.
Who is leading the discussions at the virtual symposium?
Dr. Aaron Farberg, along with dermatology students, will lead discussions on navigating melanoma diagnoses and providing emotional support resources.
How can patients learn more about Castle's tests?
Patients can find more information about Castle's tests on their official website, highlighting options available for skin cancer care.
